1. Dysfunctional Coagulation in COVID-19: From Cell to Bedside

   • Jie Wang
   • Ardan M. Saguner
   • Guoliang Li

   Commentary 05 June 2020 Pages: 3033 - 3039

   

2. A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?

   • Jie Zhang
   • Junlong Li
   • Eric Wu

   Commentary Open access 10 June 2020 Pages: 3040 - 3058

   

3. The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review

   • Hope S. Rugo
   • Ira Jacobs
   • Gabriel G. Malouf

   Review Open access 22 May 2020 Pages: 3059 - 3082

   

4. Antimicrobial De-Escalation in the ICU: From Recommendations to Level of Evidence

   • Ines Lakbar
   • Jan J. De Waele
   • Marc Leone

   Review Open access 27 May 2020 Pages: 3083 - 3096

   

5. Diagnosis and Management of Hypothyroidism in Gulf Cooperation Council (GCC) Countries

   • Ali S. Alzahrani
   • Mourad Al Mourad
   • Eslam Abdelhamid

   Review Open access 01 June 2020 Pages: 3097 - 3111

   

6. Papillary Thyroid Cancer—Aggressive Variants and Impact on Management: A Narrative Review

   • Andrés Coca-Pelaz
   • Jatin P. Shah
   • Alfio Ferlito

   Review Open access 01 June 2020 Pages: 3112 - 3128

   

7. Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study

   • Shaum M. Kabadi
   • Aimee Near
   • Chakkarin Burudpakdee

   Original Research 12 May 2020 Pages: 3129 - 3148

   

8. Correction to: Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study

   • Shaum M. Kabadi
   • Aimee Near
   • Chakkarin Burudpakdee

   Correction 13 June 2020 Pages: 3149 - 3149

9. Dual Antiplatelet Therapy Duration in Medically Managed Acute Coronary Syndrome Patients: Sub-Analysis of the OPT-CAD Study

   • Sicong Ma
   • Zaixin Jiang
   • Yaling Han

   Original Research 16 May 2020 Pages: 3150 - 3161

   

10. Correction to: Dual Antiplatelet Therapy Duration in Medically Managed Acute Coronary Syndrome Patients: Sub-Analysis of the OPT-CAD Study

    • Sicong Ma
    • Zaixin Jiang
    • Yaling Han

    Correction 09 June 2020 Pages: 3162 - 3162

11. Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy

    • James Bowen
    • Rina Mehta
    • Machaon Bonafede

    Original Research Open access 20 May 2020 Pages: 3163 - 3177

    

12. Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy

    • Maria Laura Canale
    • Andrea Camerini
    • Nicola Maurea

    Original Research Open access 20 May 2020 Pages: 3178 - 3184

13. Development and Validation of a Nomogram-Based Prognostic Evaluation Model for Sarcomatoid Hepatocellular Carcinoma

    • Dazhuang Ge
    • Zhiwen Luo
    • Jianqiang Cai

    Original Research 20 May 2020 Pages: 3185 - 3205

    

14. Treatment of Oculoplastic and Ocular Surface Disease in Eyes Implanted with a Type I Boston Keratoprosthesis in Southern China: A Retrospective Study

    • Yuying Zhang
    • Zhancong Ou
    • Jiaqi Chen

    Original Research 20 May 2020 Pages: 3206 - 3222

    

15. Persistence of Inflammation After Uncomplicated Cataract Surgery: A 6-Month Laser Flare Photometry Analysis

    • Michele De Maria
    • Marco Coassin
    • Luigi Fontana

    Original Research 21 May 2020 Pages: 3223 - 3233

    

16. Pharmacokinetics and Dialyzability of a Single Oral Dose of Amenamevir, an Anti-Herpes Drug, in Hemodialysis Patients

    • Shuichi Tsuruoka
    • Takamasa Endo
    • Naoto Hashimoto

    Original Research Open access 21 May 2020 Pages: 3234 - 3245

    

17. The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach

    • Wim A. Wuyts
    • Spyridon Papiris
    • Stéphane Soulard

    Original Research Open access 22 May 2020 Pages: 3246 - 3264

    

18. Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis

    • Derek Burns
    • Julianna Kula
    • Matthew Ornelas

    Original Research Open access 23 May 2020 Pages: 3265 - 3277

19. Prevalence and Management Challenges in Central Post-Stroke Neuropathic Pain: A Systematic Review and Meta-analysis

    • Andreas Liampas
    • Nikolaos Velidakis
    • Panagiotis Zis

    Original Research Open access 23 May 2020 Pages: 3278 - 3291

    

20. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA

    • Amy L. Olson
    • Toby M. Maher
    • Lou De Loureiro

    Original Research Open access 21 May 2020 Pages: 3292 - 3298

    

21. Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3–11 Years with Hepatitis C Genotype 1a

    • Philip Rosenthal
    • Michael R. Narkewicz
    • Daniel H. Leung

    Original Research Open access 25 May 2020 Pages: 3299 - 3310

    

22. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study

    • Yasushi Goto
    • Nobuyuki Yamamoto
    • Yuichiro Ohe

    Original Research 29 May 2020 Pages: 3311 - 3323

    

23. Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan

    • Nakao Iwata
    • Ataru Inagaki
    • Sakiko Yamada

    Original Research Open access 04 June 2020 Pages: 3324 - 3336

    

24. Troponin Levels Relate to CRP Concentrations in Patients With NAFLD on Maintenance Haemodialysis: A Retrospective Study

    • Domenico Capone
    • Mauro Vinciguerra
    • Giovanni Tarantino

    Original Research Open access 08 June 2020 Pages: 3337 - 3347

    

25. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland

    • Erkki Soini
    • Outi Virtanen
    • Aurelie Millier

    Original Research Open access 09 June 2020 Pages: 3348 - 3369

    

26. PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta^®): Pharmacodynamics, Pharmacokinetics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers

    • Shahrzad Moosavi
    • Troy Borema
    • Hsuan-Ming Yao

    Original Research Open access 10 June 2020 Pages: 3370 - 3391

    

27. Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma

    • Pranav Abraham
    • Joe Gricar
    • Veena Shankaran

    Original Research Open access 12 June 2020 Pages: 3392 - 3403

    

28. Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study—Asian Subgroup Analysis

    • Shang-Yi Huang
    • Sung-Soo Yoon
    • Chang-Ki Min

    Brief Report Open access 10 June 2020 Pages: 3404 - 3416

    

29. Etrolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease: An Overview of the Phase 3 Clinical Program

    • William J. Sandborn
    • Severine Vermeire
    • The Etrolizumab Global Steering Committee

    Study Protocol Open access 22 May 2020 Pages: 3417 - 3431

    

30. Correction to: Panel Discussion: Some Aspects of the Management of Patients with X-Linked Hypophosphataemic Rickets

    • José-Vicente Torregrosa
    • Jaime Sánchez del Pozo
    • Manuel Muñoz Torres

    Correction 23 May 2020 Pages: 3432 - 3432